Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
- 06.11.2023
- Review
Erschienen in:
- Verfasst von
- Ruben Bill
- William C. Faquin
- Sara I. Pai
- Erschienen in
- Head and Neck Pathology | Ausgabe 4/2023
Abstract
Immune checkpoint inhibitors have improved the outcome of patients diagnosed with inoperable recurrent or metastatic head and neck squamous cell carcinoma. However, as only a subset of head and neck cancer patients benefit from this treatment, biomarkers predicting treatment response help guide physicians in their clinical decision-making. PD-L1 expression assessed by immunohistochemistry is the single most clinically relevant biomarker predicting response to PD-1-blocking antibodies. Here, we discuss in which clinical context assessment of PD-L1 expression is instrumental for the choice of therapy, how pathologists score it, and how it affects the approval of anti-PD-1 antibodies. Furthermore, we discuss the heterogeneity of PD-L1 expression and review technical aspects of determining this prominent biomarker—knowledge that might influence clinical decision-making.
Anzeige
- Titel
- Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
- Verfasst von
-
Ruben Bill
William C. Faquin
Sara I. Pai
- Publikationsdatum
- 06.11.2023
- Verlag
- Springer US
- Erschienen in
-
Head and Neck Pathology / Ausgabe 4/2023
Elektronische ISSN: 1936-0568 - DOI
- https://doi.org/10.1007/s12105-023-01590-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
